CEL-SCI Corporation Releases Letter to Sh...( VIENNA Va. July 7 /- The following l...)

VIENNA, Va., July 7 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI Corporation (NYSE Amex: CVM) to its shareholders:

Dear Fellow Shareholders:

Recently we have been hearing a great deal about the pandemic caused by the H1N1 swine flu. You may think to yourself, this is no big deal since it does not seem that serious and, look what happened to bird flu - it disappeared. Wrong - on both counts! In this letter I will show you where in the world, outside of the Far East, we already have a potent reservoir of bird flu just waiting to "meet" the swine flu. Once one person infected with a combined bird/swine flu virus gets on a plane, there will be no way to contain that next stage of the continuing pandemic. CEL-SCI scientists and their collaborators are in the process of trying to develop a vaccine/treatment for this eventuality.

Before I get into more details, I want to thank my fellow shareholders for supporting us during the past 9 months of the financial crisis. The crisis severely tested us and we have become better at what we do. In the process we have also defined CEL-SCI to work in three separate business units, all designed to support each other to make an enormous difference for the world and create financial success for our shareholders.

The three business units are:

1) Vaccines/treatment: H1N1 (swine) and other influenza viruses, as

well as a vaccine for rheumatoid arthritis.

2) Unique contract manufacturing services using our new manufacturing

facility near Baltimore, MD to generate additional revenue streams.

3) Our late-stage non-toxic cancer immunotherapy, Multikine, designed

to make the first cancer treatment more successful.

'/>"/>